Skip to main content

Common Variable Immunodeficiency

3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
3 programs
1
1
VivaglobinPhase 41 trial
Human Normal Immunoglobulin for Subcutaneous AdministrationPhase 31 trial
gammaglobulinN/A1 trial
Active Trials
NCT00661401Completed5Est. Nov 2002
NCT00542997Completed51Est. Aug 2009
NCT00520494Completed18Est. Oct 2008
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
STA-5326Phase 11 trial
Active Trials
NCT00263237Completed10Est. Jul 2008
CSL Behring
CSL BehringIL - Bradley
3 programs
gammaglobulinN/A
Human Normal Immunoglobulin for Subcutaneous AdministrationPHASE_3
VivaglobinPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL SeqirusVivaglobin
CSL SeqirusHuman Normal Immunoglobulin for Subcutaneous Administration
Allergy TherapeuticsSTA-5326
CSL Seqirusgammaglobulin

Clinical Trials (4)

Total enrollment: 84 patients across 4 trials

NCT00520494CSL SeqirusVivaglobin

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

Start: Mar 2007Est. completion: Oct 200818 patients
Phase 4Completed
NCT00542997CSL SeqirusHuman Normal Immunoglobulin for Subcutaneous Administration

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

Start: Sep 2007Est. completion: Aug 200951 patients
Phase 3Completed
NCT00263237Allergy TherapeuticsSTA-5326

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

Start: Dec 2005Est. completion: Jul 200810 patients
Phase 1Completed
NCT00661401CSL Seqirusgammaglobulin

Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin

Start: Jan 2002Est. completion: Nov 20025 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.